JCR Pharmaceuticals Co., Ltd.
Life is Rare Fiscal Year Ending March 2027 Q2 Earnings Presentation
Despite a decrease in milestone revenue, Growject® progress is on schedule and Iscargo® is performing well. Full-year forecasts are maintained, but operating profit is expected to decline significantly due to increased R&D expenses. Domestic and international rollout of givinostat and new drug out-licensing will support medium- to long-term growth.
Key Figures
- Revenue: 19,974 million yen (Year-over-Year -6.5%)
- Operating Income: -3,504 million yen
- Research and Development Expenses: 10,230 million yen (Year-over-Year +2,395)
AI要約
Earnings Overview
This summarizes results for the six months ended March 2026 and key points of the full-year forecast for the fiscal year ending March 2027. Revenue declined year-over-year, impacted by delays in milestone payments. Growject® continues expansion in the domestic market, and Iscargo® is introducing new cases smoothly. R&D expenses are trending upward, which could result in an upside to the full-year forecast, although overall SG&A will be managed to stay near plan. Introduction and development of givinostat are progressing domestically and internationally.
Outlook and Impact for Investors
The full-year forecast is unchanged for now, but milestone revenue progress could lead to upside, while increased R&D spending and foreign exchange effects are expected to keep operating income under pressure. License income domestically and internationally and growth via JVs are expected to support mid-term revenue growth. M&A and partnerships for technology out-licensing remain important growth drivers to monitor.
Operating Income Trend
JCR Pharmaceuticals Co., Ltd.
Company overview · Stock price · Financial data · All IR
